- In older patients with diffuse large B-cell lymphoma (DLBCL), maintenance lenalidomide after response to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) delivered significant improvement in PFS with no meaningful effect on health-related QoL (HRQOL).
Why this matters
- The REMARC study demonstrated significant PFS improvement with maintenance lenalidomide vs placebo:
- Median PFS: not reached vs 58.9 months (HR, 0.708; 95% CI, 0.54-0.93; P=.01).
- Subpopulation analysis to investigate effects of lenalidomide maintenance (n=229) vs placebo (n=228) on HRQOL in patients with DLBCL aged ≥60 years from the REMARC study.
- Funding: Lymphoma Academic Research Organisation of France; Celgene Corporation.
- Global health status (GHS) was comparable between treatment groups throughout maintenance.
- Rates of observable treatment-emergent adverse events (TEAEs); rates of TEAEs leading to dose reduction:
- Lenalidomide group: 81.1%; 54.3%.
- Placebo group: 63.3%; 22.6%.
- HR for PFS for lenalidomide vs placebo:
- In 366 patients who received dose reduction: 0.795 (95% CI, 0.531-1.190; P=.2632).
- In 279 patients who did not receive dose reduction: 0.788 (95% CI, 0.515-1.205; P=.2694).
- No significant difference in treatment benefit regardless of dose reduction: 1.353 (P=.2978).
- Post hoc analysis.